Discover more on Bavarian Nordic's vaccine sales decline, diversification strategy, and strong Travel Health segment, ...

Danish biotech Bavarian Nordic said on Friday the order book for delivery of its vaccine for mpox and smallpox in 2025 ...

"Bavarian Nordic shares sink by 12% after mpox sales slump in Q3" was originally created and published by Pharmaceutical ...

Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

Vaccine maker Bavarian Nordic expects the incoming Trump administration to boost biodefence funding despite the nomination of ...

Bavarian Nordic A/S ( (BVNRY) ) has released its Q3 earnings. Here is a breakdown of the information Bavarian Nordic A/S presented to its ...

COPENHAGEN, Denmark, November 15, 2024 – (OMX: BAVA) announced today its interim financial results for the first nine months ...

Welcome to the Bavarian Nordic Third Quarterly Report for the Nine ... we're dealing with another -- yet another public health crisis in mpox, and we recorded very strong sales in line with ...

Danish biotech Bavarian Nordic said on Friday the order book for delivery of its vaccine for mpox and smallpox in 2025 ...

Bavarian Nordic has already secured a sizeable portion of revenue for 2025 through orders for its mpox/smallpox vaccine, but financial performance for the shot was down in Q3. The Danish ...